Late Breaker

 General hepatology

Channel 1
Abstract session
29 August 2020 13:00 - 15:00


Title Time (CET)

Add to Calendar

LBO01 Positive topline results from a 24-week, randomised, double-blind, placebo-controlled, multicentre, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
29 August 2020 13:00 - 13:15
LBO02 ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: an interventional randomised controlled trial
29 August 2020 13:15 - 13:30
LBO03 Early liver transplantation for severe alcoholic hepatitis not responding to medical treatment: results of the French-Belgian prospective study QuickTrans
29 August 2020 13:30 - 13:45
LBO04 Safety and efficacy of combination therapies including cilofexor/firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial
29 August 2020 13:45 - 14:00
LBO05 Genome-wide association study for alcohol-related cirrhosis identifies new risk loci in MARC1 and HNRNPUL1
29 August 2020 14:00 - 14:15
LBO06 Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: results of the Stop-NUC trial
29 August 2020 14:15 - 14:30
LBO07 Proton beam radiotherapy vs. radiofrequency ablation treatment in patients with recurrent hepatocellular carcinoma: a randomised controlled phase 3 non-inferiority APROH trial
29 August 2020 14:30 - 14:45
LBO08 Serum bile acid control in long-term maralixibat-treated patients is associated with native liver survival in children with progressive familial intrahepatic cholestasis due to bile salt export pump deficiency
29 August 2020 14:45 - 15:00